Best In Class

The parasympathetic nervous system is the body’s internal relaxation & rest mechanism. HRV is an indicator of Vagus Nerve activity. Improving these parameters of HRV indicates targeted stimulation of the vagus nerve and activation of psychophysiological self-repair mechanisms. In a clinical trial, a one-hour session of Nurosym favourably altered all parameters of Heart Rate Variability (HRV), when compared to a placebo.

Figure (A) shows High Frequency HRV is significantly increased (*p=0.001). Figure (B) shows Low Frequency HRV is significantly decreased (*P=0.001). Figure (C) shows the ratio of LF to HF is significantly decreased (*p=0.002).

Studies have demonstrated that pre-existing conditions such as anxiety further heighten the risk of conditions associated with chronic inflammation. Research on the Nurosym neuromodulation system has shown that it activates the vagus nerve, leading to a reduction in anxiety and stress responses. This targeted stimulation of the vagus nerve increases vagal tone and inhibits cytokine production in the inflammatory process. Both are important mechanisms for anxiety resilience.

The figure illustrates changes in anxiety across three timepoints: pre-intervention (D0), post-intervention (D10) (D0 vs D10, p < 0.001), and 1-month follow-up after accomplished treatment (D0 vs Follow-up, p < 0.001).

Nurosym neuromodulation has demonstrated a beneficial effect on fatigue by modulating the autonomic nervous system, leading to enhanced energy levels and reduced sensations of exhaustion. In the study, patients reported sustained improvements even one week after discontinuing the treatment, indicating prolonged relief from fatigue-related symptoms.

(Figure) Fatigue was assessed using the Pichot fatigue scale scores during treatment (D0: day 0, D5: day 5 and D10: day 10). The results revealed a substantial reduction in fatigue, registering approximately 48% improvement (D0 vs. D10, p < 0.0001) after Nurosym neuromodulation treatment.

In individuals with sleep onset difficulties, the sympathetic branch of the autonomic nervous system may exhibit heightened activity compared to the parasympathetic branch, resulting in increased agitation. The study demonstrated that Nurosym neuromodulation enhances parasympathetic activity, which in turn mitigates agitation and improves sleep scores.

(Figure) Changes in sleep (PROMIS Sleep Disturbance) across three timepoints: pre-intervention, post-intervention, and 1-month follow-up (*p < 0.05).

A growing body of research suggests that vagus nerve regulation plays a crucial role in managing chronic inflammation. Nurosym, through the stimulation of afferent vagus nerve fibres, has been shown to influence higher brain structures. This modulation may help alleviate symptoms connected to Long-Covid Syndrome such as chronic fatigue, pain, and brain fog.

(Figure ) A very significant improvement in Long-COVID symptoms was observed after 10 neuromodulation treatment sessions. (D0 vs. D10: p < 0.0001).

Disruption of signals in the afferent fibres of the vagus nerve can directly or indirectly induce brain disorders, including depression. Nurosym neuromodulation significantly decreased depression scores and improved mood within just 5 days of treatment, with continued improvement observed after 10 days.

(Figure) The figure shows the evolution of the Beck depression scale (D0: day 0, D5: day 5 and D10: day 10). The results showed a noticeable improvement in mood, registering approximately 45% on the Beck Depression Scale (p<0.05). 

Individuals with attention deficits, including those diagnosed with ADHD, often exhibit low heart rate variability (HRV) measurements, indicating reduced vagus nerve activity and diminished parasympathetic tone. Nurosym neuromodulation counteracts the persistent sympathetic "fight-or-flight" overdrive, thereby enhancing cognitive function.

(Figure) Changes in attention were assessed using the Flanker Inhibitory Control and Attention assay across three timepoints: pre-intervention, post-intervention, and 1-month follow-up. After Nurosym treatment, significant gains were detected from pre-intervention to post-intervention (p < 0.01) and from pre-intervention to follow-up (p < 0.001).

People who suffer from POTS or tachycardia have diminished size vagus nerves. Research team discovered that POTS symptoms were significantly lessened in people receiving Nurosym — 15 beats less per minute compared to the placebo group. Additionally, the active group showed lower levels of anti-autonomic autoantibodies (specifically α1-AR and β1-AR)

(Figure) Comparison of Orthostatic Tachycardia between Nurosym neuromodulation and placebo stimulation after a 2-Month. The figure illustrates the changes in heart rate upon standing.

Biologically, the vagus nerve inhibits oxidative stress, inflammation and sympathetic activity (and associated hypoxia). Nurosym led to a significant decrease in reactive oxygen species (ROS) (p = 0.004), while placebo stimulation did not cause a significant change (p = 0.10).

(Figure) Change in median DCF values from admission to discharge in the Nurosym group compared to the placebo group (p < 0.005).

Inflammation throughout the body and brain contributes to disease development, progression, ageing, and mental health problems. In a randomised controlled trial of Nurosym neuromodulation, inflammatory cytokines were significantly lower in the group that received Auricular Vagal Neuromodulation Therapy (AVNT) compared to the placebo group at the end of 3 months.

(Figure) The figure presents the changes in the IL-6 inflammatory biomarker compared to placebo.

Researchers have demonstrated a direct link between vagus nerve stimulation and the activation of learning centres in the brain. This discovery has led to the evaluation of Nurosym neuromodulation, which has been shown to enhance cognitive retention in both healthy individuals and those with injured nervous systems.

(Figure) Nurosym neuromodulation paired with training significantly (*p < 0.05) improved speed performance on the Automaticity learning task compared to placebo controls. Nurosym neuromodulation also significantly (∗p < 0.05) improved percent correct on the Decoding learning task as compared to controls.

The vagus nerve, through its physiological connections to various brain areas, plays a key role in modulating many behavioural processes related to memory. Nurosym research investigates enhancements in memory and neuroplasticity, linking cognitive function with the parasympathetic nervous system.

(Figure A, B) Nurosym improves memory on learning tasks in comparison to placebo. (A) There was a significant benefit of Nurosym neuromodulation compared to placebo across all test questions. (B) This effect was driven by a significant benefit of Nurosym neuromodulation on memory questions.

The vagus nerve modulates the inflammatory response, thereby reducing the systemic inflammatory burden that contributes to the progression of various diseases, including atrial fibrillation. Leveraging this mechanism, Nurosym neuromodulation offers a non-invasive modality for regulating cardiac rhythm, effectively suppressing atrial fibrillation.

(Figure) Comparison of atrial fibrillation (AF) burden between the two groups (Nurosym neuromodulation vs Placebo stimulation) is presented using interquartile range values. The p-value reflects the comparison of median AF burden levels at the 6-month mark, adjusted for baseline measurements.

Many studies have shown that drug treatments do not improve morbidity and mortality in patients after myocardial infarction. These patients often exhibit significant autonomic dysfunction, characterised by increased sympathetic nervous system activity and decreased parasympathetic (vagal) activity. The study found that Nurosym is effective by targeting cardiac inflammation and autonomic dysfunction.

(Figure) Comparison of the effect of Nurosy neuromodulation on global longitudinal strain (GLS) during active versus placebo stimulation. Active neuromodulation resulted in a significant improvement in GLS (p = 0.001) compared to sham stimulation.

The purpose of the study was to determine the influence of vagal innervation control of the resting diameter of large blood vessels using Nurosym neuromodulation. Nurosym has demonstrated a significant ability to enhance blood circulation and macrovascular endothelial function compared to a placebo.

(Figure) Percent change in flow-mediated vasodilation (FMD) with Nurosym. "Before" and "after" refer to the brachial artery (BA) diameter and FMD test conducted pre- and post-Nurosym neuromodulation. The y-axis shows the percent change in BA diameter. The box shows the 25th–75th percentile, the middle line is the median, the dot is the mean, and the bars indicate the maximum and minimum values.

Parasympathetic outflow utilises the circuit from the dorsal motor nucleus of the vagus nerve to regulate circulation. This improvement in blood circulation, or perfusion rate, is crucial for efficiently supplying oxygen and nutrients to tissues while removing waste products. The study using Nurosym indicated a trend towards enhanced microcirculatory function,

(Figure) (A) Changes in blood perfusion measured over nail bed area, before and after Nurosym neuromodulation (B) and sham (placebo) stimulation (C). Markedly higher perfusion rate was seen after Nurosym neuromodulation